Road Ahead Still Difficult for Biosimilar Producers in US

Applied Clinical Trials

The FDA has finalized its guidance on interchangeable biosimilars, but the new specifications will still make it a difficult for biosimilar producers looking to make headway in the United States. GlobalData’s Senior Immunology Pharma Analyst, Rose Joachim, weighs in.

See what she has to say here.